Selurampanel
Alternative Names: BGG-492; BGG-492ALatest Information Update: 04 Sep 2017
At a glance
- Originator Novartis
- Class Antiepileptic drugs; Pyrazoles; Sulfonamides
- Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Partial epilepsies
- Discontinued Epilepsy; Migraine; Tinnitus
Most Recent Events
- 04 Sep 2017 Discontinued - Phase-II for Epilepsy in Germany (PO)
- 04 Sep 2017 Discontinued - Phase-II for Migraine in USA, Spain and Germany (PO)
- 04 Sep 2017 Discontinued - Phase-II for Tinnitus in Netherlands and Germany (PO)